As part of the Inflation Reduction Act, price negotiations with manufacturers will begin this year, with reduced prices ...
Medicare will soon negotiate prices for 15 more drugs as part of an effort to reduce costs for seniors and people with ...
Drugs used to treat cancer, diabetes and other chronic conditions are among 15 picked for negotiations that could result in ...
The rescinded order directed Medicare and Medicaid to test ways to lower drug costs for enrollees. Those tests hadn’t started ...
The Centers for Medicare & Medicaid Services announced 15 new drugs it wants to lower the cost for, including popular, but ...
The talks around drugs including Novo Nordisk's Wegovy, GSK's Trelegy Ellipta, and Pfizer's Xtandi will set Medicare prices ...
The Biden Administration announced the next batch of 15 prescription drugs that will be included in price negotiations with companies — with the aim of lowering costs for people covered by Medicare.
The U.S. Centers for Medicare and Medicaid Services released its list of drugs covered under Medicare Part D selected for the ...
Experts suggest that most Americans will not experience immediate changes in their out-of-pocket health care expenses.
Ozempic and Wegovy, Novo Nordisk’s GLP-1 drugs that treat diabetes and obesity, are on the list. Astellas Pharma’s prostate cancer drug, Xtandi, is also on the list — alongside AstraZeneca’s cancer ...
On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in ...
Xavier Becerra is reflecting on tenure as HHS secretary. He told Scripps News, "We're leaving this country is healthier and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback